UCB’s Vimpat NDA Seeks Indications For Epileptic Seizures, Diabetic Pain
This article was originally published in The Pink Sheet Daily
Executive Summary
Belgian firm has an anticipated July 2008 user fee date for lacosamide, which was submitted as a single NDA with two indications, for partial onset seizures in epilepsy and diabetic neuropathic pain.
You may also be interested in...
UCB’s Vimpat Falters In Diabetic Pain
Neuropathy filing is "not approvable" at FDA, but seizure indication is on track, firm says.
UCB’s Vimpat Falters In Diabetic Pain
Neuropathy filing is "not approvable" at FDA, but seizure indication is on track, firm says.
CHMP Recommends Three Approvals And Two Label Expansions, Makes One Denial
EMEA recommends against use of epoetins in some cancer patients.